Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor

Abstract excerpt

The successful genetic engineering of patient T cells with γ-retroviral vectors expressing chimeric antigen receptors or T-cell receptors for phase II clinical trials and beyond requires the large-scale manufacture of high-titer vector stocks. The production of retroviral vectors from stable packaging cell lines using roller bottles or 10- to 40-layer cell factories is limited by a narrow harvest window, labor...

Topics

Join the communities discussing this publication.

• CAR-T cell therapy research
• Viral Infectious Diseases and Gene Expression in Insects
• Virus-based gene therapy research